drugset
drugset / Trial / NCT01094977

Blood Loss and Transfusion Requirement in Infants Treated With Tranexamic Acid

NCT01094977 ↗

Phase 3 Suspended 90 enrolled The Hospital for Sick Children
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective of this study is to investigate whether tranexamic acid (TXA) reduces perioperative blood loss and transfusion requirement in infants undergoing craniosynostosis surgery.

Timeline

Start
2010-01
Primary completion
2020-01
Completion
2020-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 5 mg/kg —
Subject Tranexamic Acid Small molecule 10 mg/kg —

Indications

craniosynostosis